Skip to main content

Table 2 Summary of EAE clinical scores

From: Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis

Group Incidence/total (%) Number of mice dead Disease onset (days)a Clinical scores (mean ± SE)
pid-20b pid-40c
EAE 11/11 (100%) 0 10.9 ± 0.71 2.27 ± 0.12 2.14 ± 0.10
EAE/glib-pid-12 10/10 (100%) 1 10.7 ± 0.27 1.20 ± 0.32 0.78 ± 0.28
EAE/glib-pid-24 12/12 (100%) 0 11.7 ± 0.80 2.21 ± 0.17 1.17 ± 0.24
  1. aDisease onset is defined as the first day of a clinical score of one or more. There was no statistically significant difference in day of disease onset between groups
  2. bThe Kruskall-Wallis test indicated a significant difference between groups (P = 0.0257) on pid-20, with Dunn’s post hoc comparisons indicating that the EAE group was statistically different compared to the EAE/glib-pid-12 group (P < 0.05); the EAE and EAE/glib-pid-24 groups were not statistically different
  3. cThe Kruskall-Wallis test indicated a significant difference between groups (P = 0.0010) on pid-40, with Dunn’s post hoc comparisons indicating that the EAE group was statistically different compared to both the EAE/glib-pid-12 (P < 0.01) and the EAE/glib-pid-24 (P < 0.05) groups; the EAE/glib-pid-12 and EAE/glib-pid-24 groups were not statistically different